LakeShore Biopharma Director Resigns

Ticker: LSBWF · Form: 6-K · Filed: May 12, 2025 · CIK: 1946399

Lakeshore Biopharma CO., LTD. 6-K Filing Summary
FieldDetail
CompanyLakeshore Biopharma CO., LTD. (LSBWF)
Form Type6-K
Filed DateMay 12, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: director-resignation, corporate-governance, biopharma

TL;DR

LakeShore Biopharma director Dave Chenn out, effective May 12, 2025.

AI Summary

LakeShore Biopharma Co., Ltd. announced on May 12, 2025, that Mr. Dave Chenn has resigned as a member of its board of directors. The company, formerly known as YS Biopharma Co., Ltd. and YishengBio Co., Ltd., is based in Beijing, PRC.

Why It Matters

A change in board composition can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: low — This filing is a routine report of a director's resignation and does not contain significant financial or operational news.

Key Players & Entities

FAQ

Who is LakeShore Biopharma Co., Ltd.?

LakeShore Biopharma Co., Ltd. is a pharmaceutical preparations company based in Beijing, PRC, formerly known as YS Biopharma Co., Ltd. and YishengBio Co., Ltd.

What is the purpose of this 6-K filing?

This 6-K filing is a Report of Foreign Private Issuer for the month of May 2025, announcing a change in the company's board of directors.

When was LakeShore Biopharma Co., Ltd. formerly known as YS Biopharma Co., Ltd.?

The company changed its name from YS Biopharma Co., Ltd. on March 10, 2023.

What is the principal executive office address of LakeShore Biopharma?

The principal executive offices are located at Building No. 2, 38 Yongda Road, Daxing Biomedical Industry Park, Daxing District, Beijing, PRC.

What is the SIC code for LakeShore Biopharma?

The Standard Industrial Classification (SIC) code for LakeShore Biopharma is 2834, which corresponds to Pharmaceutical Preparations.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on May 12, 2025 by Dave Chenn regarding LakeShore Biopharma Co., Ltd. (LSBWF).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing